Advertisement

When the Mind Does Not Work as It Should

  • Francesca Alemanno
  • Fernando Alemanno
Chapter

Abstract

The authors consider the possible correlations between certain alterations of the neurotransmitters of the central nervous system and two common clinical syndromes: schizophrenia and depression.

Keywords

Schizophrenia Depression Dopamine and schizophrenia Substance P and schizophrenia Glutamate and GABA in schizophrenia Acetylcholine and schizophrenia Serotonin and depression Inhibition of the action 

References

  1. 1.
    Afro Publio Terenzio. Phormio. (160 a. C.) Atto IV, scena prima, 9.Google Scholar
  2. 2.
    Eugen B. Dementia praecox, oder Gruppe der Schizophrenien. Leipzig: Duticke Verlag; 1911.Google Scholar
  3. 3.
    Herman W. The Caine Mutiny. New York: Doubleday Publisher; 1951.Google Scholar
  4. 4.
    Aiazzi Mancini M, Donatelli L. Trattato di farmacologia. Milano: Francesco Vallardi Editore; 1969.Google Scholar
  5. 5.
    Bernsohn J, Namajuk J, Cchrane LS. Inhibition of brain cytochrome oxidase and ATP-ase by chloropromazine analogues. Proc Soc Exp Biol Med. 1956;92:201–3.PubMedCrossRefGoogle Scholar
  6. 6.
    Laborit H. Les Régulations metaboliques. Paris: Masson & Cie Editeurs; 1965.Google Scholar
  7. 7.
    Laborit H, Huguenard P, Allaume R. Un nouvou stabilisateurr vegetatif : le 4560 RP (chloropromazine). Presse méd. 1952;60(10):206–8.Google Scholar
  8. 8.
    Bear MF, Connors BW, Paradiso MA. Neuroscience: exploring the brain—third edition. New York: Lippincot Williams & Wilkins; 2007.Google Scholar
  9. 9.
    Meltzer HY. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology. 1989;99(1., Supplement):S18–27.PubMedCrossRefGoogle Scholar
  10. 10.
  11. 11.
    Coyle JT, et al. Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia. Dialogues Clin Neurosci. 2010;12(3):359–82.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Kartvelishvily E, Shleper M, et al. Neuronderived D-serine release provides a novel means to activate N-methyl-D-aspartate receptors. J Biol Chem. 2006;281:14151–62.PubMedCrossRefGoogle Scholar
  13. 13.
    Caulfield MP, Birdsall NJ. International Union of Pharmacology, XVII. Classification of muscarinic receptors. Pharmacol Rev. 1998;50:279–90.PubMedGoogle Scholar
  14. 14.
    Shekhar A, Potter WZ, Lightfoot J, et al. Selective muscarinic receptors agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry. 2008;165:1033–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Figiel G, Sadowsky C. A systematic review of the effectiveness of rivastigmine for the treatment of behavioral disturbances in dementia and other neurologic disorders. Curr Med Res Opin. 2008;24:157–66.PubMedCrossRefGoogle Scholar
  16. 16.
    Grossberg GT. Effect of rivastigmine in the treatment of behavioral disturbances associated with dementia; review of neuropsychiatric impairment in Alzheimer’s disease. Curr Med Res Opin. 2005;21:1631–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Dean B, McLeod M, Keriakous D, McKenzie J, Scarr E. Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry. 2002;7:1083–91.PubMedCrossRefGoogle Scholar
  18. 18.
    KSP A, Höglund AU. Intravenously administered oxotremorine and atropine, in doses known to affect pain threshold, affect the intraspinal release of acetylcholine in rats. Pharmacol Toxicol. 2002;90:187–92.CrossRefGoogle Scholar
  19. 19.
    Bartolini A, Ghelardini C, Fantetti L, et al. Role of muscrinic receptor subtypes in central antinoception. Br J Pharmacol. 1992;105:77–82.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Baba H, et al. Muscarinic facilitation of GABA release in substantia gelatinosa of the rat spinal dorsal horn. J Physiol. 1998;508:83–93.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Yegin A, Yilmaz M, Karsli B, Erman M. Analgesic effects of intrathecal neostigmine in perianal surgery. Eur J Anaesthesiol. 2003;20:404–8.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Gupta S. Postoperative analgesia with intrathecal neostigmina; two 75 mcg and 50 mcg with heavy bupivacaine. Internet J Anesthesiol. 2008;25:1.Google Scholar
  23. 23.
    Kaya FN, Sahin S, Owen MD, Eisenach JC. Epidural neostigmine produces analgesia but also sedation in women after caesarean delivery. Anesthesiology. 2004;100:381–5.PubMedCrossRefGoogle Scholar
  24. 24.
    Lauretti GE, De Oliveira R, Reis MP, et al. Study of three different doses of epidural neostigmina coadministered with lidocaine for postoperative analgesia. Anesthesiology. 1999;90(6):1534–8.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Buaziz H, Paqueron X, Bur ML, Merle M, Laxenaire MC, Benhamou D. No enhancement of sensory and motor blockade by neostigmine added to mepivacaina axillary plexus. Anesthesiology. 1999;91(1):78–83.CrossRefGoogle Scholar
  26. 26.
    Alemanno F, Ghisi D, Westermann B, Bettoni A, Fanelli A, LaColla L, Danelli G, Cesana BM. The use of vitamin B1 as a perineural adjuvant to the Middle Interscalene Block for postoperative analgesia after shoulder surgery. Acta Biomed. 2016;87(1):22–7.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Kumary V, Postma V. Nicotine use in schizophrenia: the self-medication hypothesis. Neurosci Biobehav Rev. 2005;6(29):1021–34.CrossRefGoogle Scholar
  28. 28.
    Gray R, Rajan AS, Radcliffe KA, Yakeiro M, Dani JA. Hippocampal synaptic transmission enhanced by low concentrations of nicotine. Nature. 1996;383:713–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Von Euler US, Gaddum JH. An unidentified depressor substance in certain tissue extracts. J Physiol. 1931;72(1):74–87.CrossRefGoogle Scholar
  30. 30.
    Massoni E, Bersani G. Possibile ruolo della sostanza P e del suo recettore NK1 nei disturbi dell’umore ed in condizioni psichiatriche. Riv Psichiatr. 2003;38(6):289–95.Google Scholar
  31. 31.
    Sergeyev V, Hokfelt T, Hurd Y. Serotonin and substance P co-exist in dorsal raphe neurons of the human brain. Neuroreport. 1999;10:3967–70.PubMedCrossRefGoogle Scholar
  32. 32.
    Roberts GW, et al. Peptides, the limbic lobe and schizophrenia. Brain Res. 1983;288:199–211.PubMedCrossRefGoogle Scholar
  33. 33.
    Tezzon Frediano (Head Neurologist, Merano General Hospital). Comment on re-reading this chapter (in the text). March 2016.Google Scholar
  34. 34.
    Bellucci G. Storia dell’Anestesiologia. Padova: Piccin Editore; 1982. p. 389–92.Google Scholar
  35. 35.
    Bondy B, Baghai TC, et al. Substance P serum levels are increased in major depression: preliminary results. Biol Psychiatry. 2003;53(6):538–42.PubMedCrossRefGoogle Scholar
  36. 36.
    Keller M, Montgomery S. Lack of efficacy of the substance P (Neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry. 2006;59:216–23.PubMedCrossRefGoogle Scholar
  37. 37.
    Stout SC, Owens MJ, Nemeroff CB. Neurokinin (1) receptor antagonists as potential antidepressant. Ann Rev Pharmacol Toxicol. 2001;41:877–906.CrossRefGoogle Scholar
  38. 38.
    Nemeroff CB, Widerlov E, Bisette G, Nemeroff CB. Elevated concentrations of CSF corticotropin releasing factor-like immunoreactivity in depressed patients. Science. 1984;22:1343–4.Google Scholar
  39. 39.
    Galeno di Pergamo, De Tumoribus. Citato in: Cosmacini G, Sironi VA. Il male del secolo, per una storia del cancro. Roma-Bari: Laterza Editore; 2002.Google Scholar
  40. 40.
    Sirtori C. Atti del “Symposium Cancro del Polmone”. Introduzione biologica generale. Milano, Ospedale Maggiore “Ca Granda”, 22 giugno 1968.Google Scholar
  41. 41.
    Laborit H. Elogio della fuga. Milano: Mondadori; 1982.Google Scholar
  42. 42.
    Laborit H. La colombe assasinée. Paris: Editions Grusset & Fasquelle; 1983.Google Scholar

Further Reading

  1. Axelsson K, Gupta A. Local anaesthetic adjuvants: neuraxial versus peripheral nerve blocks. Curr Opin Anaesthesiol. 2009;22:649–54.PubMedCrossRefGoogle Scholar
  2. Bear MF, Connors BW, Paradiso MA. Neuroscienze: Esplorando il cervello. Milano: Elsevier – Masson; 2009.Google Scholar
  3. Brown JL, et al. Morphological characterization of substance P receptor-immunoreactive neurons in the rat spinal cord and trigeminal nucleus caudalis. J Comp Neurol. 1995;356:327–44.CrossRefGoogle Scholar
  4. Bymaster FP, Carter PA, Yamada M, et al. Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity. Eur J Neurosci. 2003;17:1403–10.PubMedCrossRefGoogle Scholar
  5. Frotscher M, Leranth C. Cholinergic innervation of the rat hippocampus as revealed by choline acetyltransferase immunocytochemistry; a combined light and electron microscopic study. J Comp Neurol. 1985;239:237–46.PubMedCrossRefGoogle Scholar
  6. Galzigna L. Il Cervello dell’Uomo. Ferrara: Corso Editore; 1976.Google Scholar
  7. Gillespie CF, Nemeroff CB. Hypercortisolemia and depression psychosomatic medicine. J Biobehav Med. 2005;67:S26–8.Google Scholar
  8. Gozzano M. Compendio di psichiatria. Torino: Rosenberg & Sellier; 1964.Google Scholar
  9. Heim C, Newport DJ, Bonsall R, Miller AH, Nemeroff CB. Altered pituitary-adrenal axis responses to provocative challenge tests in adult survivors of childhood abuse. Am J Psychiatry. 2001;158:575–81.PubMedCrossRefGoogle Scholar
  10. Hood DD, Eisenach JC, Tuttle RRN. Phase I. Safety assessment of intrathecal neostigmine methylsulfate in humans. Anesthesiology. 1995;82:331–43.PubMedPubMedCentralCrossRefGoogle Scholar
  11. Kramer MS, Winokur A, et al. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology. 2004;29(2):385–92.PubMedCrossRefGoogle Scholar
  12. Labrie V, Fukumura R, Rastogi A, et al. Serine racemase is associated with schizophrenia susceptibility in humans and in a mouse model. Hum Mol Genet. 2009;18:3227–43.PubMedPubMedCentralCrossRefGoogle Scholar
  13. Lewis DA, Fashimoto T, Volk DW. Cortical inhibitory neurons and schizophrenia. Nat Rev. Neurosci. 2005;6:312–24.PubMedCrossRefGoogle Scholar
  14. Morita Y, Ujike H, Tanaka Y, Otani K, et al. A genetic variant of serine racemase gene is associated with schizophrenia. Biol Psychiatry. 2006;61:1200–3.PubMedCrossRefGoogle Scholar
  15. Murphy DB, McCartney CJ, Chan VW. Novel analgesic adjuncts for brachial plexus block: a systematic review. Anesth Analg. 2000;90:1122–8.PubMedCrossRefGoogle Scholar
  16. Schwarz MJ, Ackenheil M. The role of substance P in depression. Dialogues Clin Neurosci. 2002;4(1):21–9.PubMedPubMedCentralGoogle Scholar
  17. Spokes EG. An analysis of factors influencing measurements of dopamine, noradrenaline, glutamate decarboxylase and choline acetylase in human post- mortem brain tissue. Brain. 1979;102:333–46.PubMedCrossRefGoogle Scholar
  18. Toru M, et al. Neurotransmitters, receptors and neuropeptides in post-mortem brains of chronic schizophrenic patients. Acta Psychiatr Scand. 1988;78:121–37.PubMedCrossRefGoogle Scholar
  19. Kramer MS, Winokur A, et al. Demonstration of the efficacy and safety of a novel substance P (NK 1) receptor antagonist in major depression. Neuropsychopharmacology. 2004;29:385–92.PubMedCrossRefGoogle Scholar
  20. Wolosker H, Blackshaw S, Snyder SH. Serine racemase: a glial enzyme synthesizing D-serine to regulate glutamate-N-methyl-D-aspartate neurotransmission. Proc Natl Sci U S A. 1999;96:13409–14.CrossRefGoogle Scholar
  21. www.psicologi-italia.it/.../depressione/1081/depressione-serotonina.htmlGoogle Scholar
  22. Yaksh TI, Dirksen R, Haty GJ. Antinoceptive effects of intrathecally injected cholinomimetic drugs in the rat and cat. Eur J Pharmacol. 1985;117:81–8.PubMedPubMedCentralCrossRefGoogle Scholar
  23. Zhang Y, Behrens MM, Lisman JE. Prolonged exposure to NMDA antagonist suppresses inhibitory synaptic transmission in prefrontal cortex. J Neurophysiol. 2008;100:959–65.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Francesca Alemanno
    • 1
  • Fernando Alemanno
    • 2
  1. 1.PsychologyUniversity of PadoaPadoaItaly
  2. 2.Anaesthesia and Intensive CareBrescia Clinical InstitutesBresciaItaly

Personalised recommendations